WifOR Study

Measuring the Economic Footprint of the Biotechnology Industry in the European Union

"Measuring the Economic Footprint of the Biotechnology Industry in the European Union" is an economic impact study commissioned by EuropaBio and conducted by the WifOR Institute to quantify the contribution of biotechnology to the EU economy. It has a particular focus on trends in growth, starting from 2008 and in the most recent edition tracking economic data to 2024.

The study examines the sector’s contribution to economic growth and employment, alongside productivity, trade and research and development. By measuring the direct, indirect and induced effects of biotechnology across European value chains, it provides a comprehensive picture of the industry’s economic footprint and its wider contribution to the EU economy.

The study covers 68 biotechnology-related products across healthcare and industrial applications, plus agriculture, which is measured separately.

The study was originally published in 2020, with subsequent editions in 2024 and 2026.

 

Key Publications

 

 

The Study at a Glance

 

Gross Value Added

€42.2

billion


Gross value added (GVA) from biotechnology activities reached €42.2 billion in 2024, almost doubling since 2008.

Labour Productivity

€188,400

GVA per person employed


Biotechnology remains one of the most economically productive industries in the EU. In 2024, across all sectors, it generated €188,400 GVA per person employed.

Trade & Exports

€91.9

billion


Biotechnology outputs deliver a significant trade surplus for the EU with its global trading partners, at a value of €91.9 billion in 2024, continuing an upward trajectory since 2008, delivering an eightfold increase.

Employment Growth

4x

higher than overall EU economy


Pace of employment growth in biotechnology in 2024 was almost four times higher than the overall EU economy.

 

Previous Publications Archive

 

  • ASSOBIOTEC
  • BioPharmaChem Ireland
  • Finnish BioIndustries
  • Bioeconomy for Change
  • Alexion AstraZeneca Rare Disease
  • Abolis
  • LithuaniaBIO
  • Health & Life Sciences cluster Bulgaria
  • AB Enzymes
  • Biovia
  • Verley Food
  • Phytolon
  • Freget Glaser & Associes
  • The Union of Biotechnological Companies BioForum
  • SwiftPharma
  • Disc Medicine
  • Cytiva
  • 21st Bio
  • SwedenBIO
  • Ajinomoto Europe
  • Genopole
  • X.DeepTech
  • DNA Script
  • Sicos
  • Gourmey
  • Formo
  • LanzaTech
  • Syensqo
  • Standing ovation
  • Biocatalyst
  • WHC Lab Ltd
  • Probiotic Group
  • Prague.bio
  • OM Pharma
  • Enduro Genetics
  • ShakeUp Factory
  • Kintiga
  • BIBRT
  • BBEU
  • Roebling (ex Synonym)
  • Vintura
  • Bronkhorst
  • Syneos
  • Sartorius
  • Dansk Biotek
  • Adisseo
  • Hawkwood Biotech
  • Ecolab
  • Vial
  • Slovenia Biotech Hills
  • Apellis
  • Ribbon Bio GmbH
  • Grittgene
  • Nestlé
  • Biotech Austria
  • BRAL
  • BeneMeat Technologies
  • Niconex
  • Pivot Bio
  • Technovative Solutions
  • CrystalsFirst
  • The Baker Company
  • LIST
  • BBIA
  • EUCROF
  • Biocat
  • Olon
  • Rhygaze Ag
  • dsm-firmenich
  • SFL